Purdue Abuse Study May Create Ongoing Challenge For Generic Entry
This article was originally published in The Pink Sheet Daily
Executive Summary
OxyContin’s three-year data exclusivity for study of intranasal liking might be just the beginning of labeling hurdles for ANDAs.
You may also be interested in...
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.
OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting
There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.
Generics Savings Once Again Could Help A Major US Health Care Reform Bill
A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.